A Recombinant Human Serum Albumin Nanoparticle Encapsulating Dimyristoyl Gemcitabine Remodels the Fibrotic Microenvironment to Potentiate Chemo-Immunotherapy in Pancreatic Cancer

Abstract Pancreatic cancer is malignant and highly lethal, largely due to a dense, fibrotic tumor stroma that fosters a profoundly immunosuppressive microenvironment and obstructs drug delivery. To overcome these barriers, we developed a novel recombinant human serum albumin-based nanoparticle encapsulating dimyristoyl GEM (dm-rHSA-NPs). In vivo, dm-rHSA-NPs achieved significant tumor accumulation with the assistance of extended half-life (3.91 vs. 0.82 h, vs. GEM) and tumor targeting ability of the rHSA-based nanoparticles. Upon reaching the tumor tissue, dm-rHSA-NPs exhibited highly efficient tumor penetration and fibrotic stroma degradation, leading to adequate cellular accumulation, further assisting in improved cellular apoptosis, decreased cellular migration and invasion, as well as ICD-inducing ability. Benefiting from these effects, the profound immunosuppression characteristic of pancreatic cancer was relieved, promoting DCs maturation (22-fold), increasing infiltration of CTLs (45-fold), and decreasing the infiltration of Tregs (3.9-fold) in the tumor. All these synergistic effects contributed to the excellent in vivo anti-pancreatic cancer efficacy (89% vs. 37% of the tumor-inhibition rate), an outstanding tumor metastasis inhibition ability (2 vs. 22 of the tumor metastasis sites), and negligible systemic toxicity, superior to GEM. By combining enhanced drug delivery with potent TME remodeling and immune activation, dm-rHSA-NPs represent a promising formulation with high potential in clinical application to treat pancreatic cancer.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-16
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c00872
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Recombinant Human Serum Albumin Nanoparticle Encapsulating Dimyristoyl Gemcitabine Remodels the Fibrotic Microenvironment to Potentiate Chemo-Immunotherapy in Pancreatic Cancer

邢超凡, Guangzhi Shan, 汪阿鹏, 夏桂敏 et al.
Molecular Pharmaceutics
Nanoparticle-Based Drug Delivery
article

A Recombinant Human Serum Albumin Nanoparticle Encapsulating Dimyristoyl Gemcitabine Remodels the Fibrotic Microenvironment to Potentiate Chemo-Immunotherapy in Pancreatic Cancer

邢超凡, Guangzhi Shan, 汪阿鹏, 夏桂敏, Xiaoru Guo, Xiaowei Wang, Jiayi Su, Mingliang Liu, Boyuan Liu, Xuelei Wang, Yiqian Li
article en

Abstract

Abstract Pancreatic cancer is malignant and highly lethal, largely due to a dense, fibrotic tumor stroma that fosters a profoundly immunosuppressive microenvironment and obstructs drug delivery. To overcome these barriers, we developed a novel recombinant human serum albumin-based nanoparticle encapsulating dimyristoyl GEM (dm-rHSA-NPs). In vivo, dm-rHSA-NPs achieved significant tumor accumulation with the assistance of extended half-life (3.91 vs. 0.82 h, vs. GEM) and tumor targeting ability of the rHSA-based nanoparticles. Upon reaching the tumor tissue, dm-rHSA-NPs exhibited highly efficient tumor penetration and fibrotic stroma degradation, leading to adequate cellular accumulation, further assisting in improved cellular apoptosis, decreased cellular migration and invasion, as well as ICD-inducing ability. Benefiting from these effects, the profound immunosuppression characteristic of pancreatic cancer was relieved, promoting DCs maturation (22-fold), increasing infiltration of CTLs (45-fold), and decreasing the infiltration of Tregs (3.9-fold) in the tumor. All these synergistic effects contributed to the excellent in vivo anti-pancreatic cancer efficacy (89% vs. 37% of the tumor-inhibition rate), an outstanding tumor metastasis inhibition ability (2 vs. 22 of the tumor metastasis sites), and negligible systemic toxicity, superior to GEM. By combining enhanced drug delivery with potent TME remodeling and immune activation, dm-rHSA-NPs represent a promising formulation with high potential in clinical application to treat pancreatic cancer.

Molecular Pharmaceutics
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon